Results 11 to 20 of about 6,372,774 (389)

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? [PDF]

open access: yesFrontiers in Oncology, 2021
Genes encoding subunits of SWItch/Sucrose Non-Fermenting (SWI/SNF) chromatin remodeling complexes are collectively mutated in 20% of all human cancers, among which the AT-rich interacting domain−containing protein 1A (ARID1A, also known as BAF250a, B120, C1orf4, Osa1) that encodes protein ARID1A is the most frequently mutated, and mutations in ARID1A ...
Shouying Xu, Chao Tang
openaire   +4 more sources

Tumor Hypoxia and Circulating Tumor Cells [PDF]

open access: yesInternational Journal of Molecular Sciences, 2020
Circulating tumor cells (CTCs) are a rare tumor cell subpopulation induced and selected by the tumor microenvironment’s extreme conditions. Under hypoxia and starvation, these aggressive and invasive cells are able to invade the lymphatic and circulatory systems.
Tinganelli W., Durante M.
openaire   +5 more sources

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

open access: yesNeuro-Oncology, 2020
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the largest population-based registry focused exclusively on primary brain and other ...
Q. Ostrom   +5 more
semanticscholar   +1 more source

Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report

open access: yesCase Reports in Oncological Medicine, 2021
The arrival of subsequent generations of tyrosine-kinase inhibitors (TKIs) has significantly broaden the EGFR-mutated lung cancer therapeutic landscape.
Víctor Albarrán   +7 more
doaj   +1 more source

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

open access: yesNature Communications, 2020
Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor ...
Daniel Baumann   +14 more
doaj   +1 more source

Tumor Microenvironment [PDF]

open access: yesMedicina, 2019
Background and Objectives: The tumor microenvironment has been widely implicated in tumorigenesis because it harbors tumor cells that interact with surrounding cells through the circulatory and lymphatic systems to influence the development and progression of cancer.
Arneth, Borros   +1 more
openaire   +4 more sources

Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma

open access: yesJournal of Immunology Research, 2022
Pancreatic adenocarcinoma (PAAD) is the most common primary malignancy of the pancreas. Growing studies indicate that transcription factors (TFs) are abnormally expressed in PAAD.
Xianbin Zhang   +4 more
doaj   +1 more source

Lacrimal gland tumors in Turkey: types, frequency, and outcomes. [PDF]

open access: yes, 2018
AIM: To evaluate the clinical, radiological, and treatment features of lacrimal gland tumors. METHODS: Retrospective review of 99 eyes of 92 patients with lacrimal gland tumors diagnosed and managed in a single institution between January 1999 and March ...
Erden, Esra   +3 more
core   +2 more sources

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

open access: yes, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch   +62 more
core   +1 more source

Tumoral calcinosis [PDF]

open access: yesJournal of Inherited Metabolic Disease, 2010
Contains fulltext : 87587.pdf (Publisher’s version ) (Open Access)
Janssen, M.C.H., Sevaux, R.G.L. de
openaire   +4 more sources

Home - About - Disclaimer - Privacy